- Overview
- Activity Format and Credit
- Register for Webinar
- The Importance of Rett Syndrome Education
- Bonus Commentary
- Overview
-
More
- Activity Format and Credit
- Register for Webinar
- The Importance of Rett Syndrome Education
- Bonus Commentary
- Sessions
STATEMENT OF NEED
Rett syndrome is a rare, debilitating neurodevelopmental disorder almost always associated with a spontaneous mutation in the methyl-CpG-binding protein 2 (MECP2) gene on the X-chromosome. Affected individuals experience loss of purposeful hand skills, abnormalities in gait, loss of spoken language, and stereotypic hand movements, with more severe manifestations including seizures, autistic features, autonomic nervous system dysfunction, breathing abnormalities, sleep disturbances, and cardiac abnormalities. While therapies for Rett syndrome are being investigated in clinical trials and have demonstrated modest benefit, no curative or effective disease-modifying treatments currently exist (Petriti et al, 2023). Therefore, the multidisciplinary team is challenged with the optimal management of complex comorbidities that persist throughout patients’ lives. This Live or Virtual Visiting Faculty Series led by Timothy John Feyma, MD, Pediatric Neurologist at Gilette Children’s Hospital, will explore novel treatments and quality-of-life improvement strategies for children and adults with Rett syndrome.
TARGET AUDIENCE
Pediatric and adult neurologists, pediatricians, internists, family physicians, child and adult psychiatrists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of children and adults with Rett syndrome.
LEARNING OBJECTIVES
- Identify distinguishing features of Rett syndrome that can inform early and accurate diagnosis
- Evaluate the safety, efficacy, and clinical utility of novel and emerging treatments for Rett syndrome in children and adults
- Devise strategies to monitor and manage Rett Syndrome symptoms in children and adults
REGISTRATION
There is no fee to participate in or claim CME/NCPD credit for this activity. REGISTER NOW
PROVIDED BY
JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.9 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Timothy John Feyma, MD, discloses that he has served on a speaker's bureau for Acadia Pharmaceuticals and PTC Therapeutics.
David N. Lieberman MD, PhD, discloses that he has served as a consultant for Acadia, Neurogene, and Taysha Gene Therapies.
Shannon M. Standridge, DO, MPH, discloses that she has served on an advisory board/panel for Acadia Pharmaceuticals and that she has served as a consultant for Acadia Pharmaceuticals.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from ACADIA Pharmaceuticals.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
FORMAT
Live Webinar
CREDIT
1.0 AMA PRA Category 1 Credit™
1.0 ANCC contact hour
0.9 contact hours of pharmacotherapy content for APRNs
ESTIMATED TIME TO COMPLETE
1 hour
DATE AVAILABLE
Thursday, November 21, 2024 at 2:00 PM ET
Rett syndrome is a rare, debilitating neurodevelopmental disorder in which complex comorbidities persist throughout patients' lives. While therapies for Rett syndrome are under investigation, no curative or effective disease-modifying treatments currently exist, and the interprofessional team is challenged with managing patients' comorbidities and optimizing quality of life.
Join Dr. David Lieberman on 11/21/24 at 2:00 pm ET and gain expert perspectives on the following:
- Distinguishing features of Rett syndrome that can inform early diagnosis
- The role of MECP2 gene sequencing in Rett syndrome
- Efficacy of novel therapies for Rett syndrome, including trofinetide
- Prevention and management of toxicities associated with trofinetide
- Supportive care strategies for managing comorbidities and enhancing quality of life for patients with Rett syndrome
- Resources for caregivers of patients with Rett syndrome
- And much more!
"Patients are the focus. Rett syndrome requires a multidisciplinary team with multiple providers, whether it's neurology, pediatrics, rehabilitation medicine, pulmonology, neurology, or therapies, and not every patient will need every discipline” - Timothy John Feyma, MD, Pediatric Neurologist at Gilette Children’s Hospital
Watch this short clip of this expert led activity that can be scheduled today for your institution.
Why it is important to educate your team on Rett Syndrome:
- Approximately 6,000-9,000 individuals are living with Rett syndrome in the US, and due to its low incidence, quality education for the interdisciplinary team is sparse
- Clinicians across a broad range of specialties should be familiar with distinguishing features of Rett syndrome in order to inform early and accurate diagnosis
- While new treatments are being developed, trofinetide is the only FDA-approved treatment specifically for Rett syndrome, and clinicians should be educated on its optimal use
- Rett syndrome has far-reaching comorbidities including respiratory, neurologic, cardiac, endocrine, gastrointestinal, and orthopedic symptoms, and timely management of comorbidities by the interdisciplinary team is crucial
- Patient and caregiver experiences can be optimized when clinicians from a broad range of specialties are familiar with the latest developments in Rett syndrom
Additional Advances in Rett Syndrome Research and Clinical Trials With Timothy John Feyma, MD
Dr. Timothy John Feyma, Pediatric Neurologist at Gillette Children’s Hospital, is currently serving as chair of i3 Health’s CME/NCPD activity, Exploring Novel Treatments for Rett Syndrome. With new developments in the field occurring over recent months, Dr. Feyma sat down with us again to share new updates in treatment and management of Rett syndrome, words of advice for how clinicians can best care for their patients, and what he is most looking forward to seeing in Rett syndrome research in the coming years.